Comparison Of Histomorphology, Angiogenesis and Proliferation in Kappa and Lambda Restricted Plasma Cell Myelomas with Its
Effect on Prognosis
Sarah Grace Priyadarshini, Debdatta Basu, Rakhee Kar, T.K. Dutta*.
Abstract
Aims Of the Study: To study the type of light chain restriction and correlate it with the morphological parameters,
proliferation index, angiogenesis and clinical parameters.
Materials And Methods: The study includes 46 cases of myeloma diagnosed over the period of five years. The
histomorphological features like plasma cell morphology, percentage of plasma cells and pattern of infiltration were
studied. Immunohistochemistry for kappa and lambda light chains was done. Angiogenesis was assessed by calculating the
microvessel density (MVD) using anti CD34 immunohistochemistry. Proliferation was assessed immunohistochemically
using Ki67 by comparing with anti CD38 which was used to highlight the plasma cells.
Results: The cases with kappa light chain restriction had significantly less of poorly differentiated morphology (7.4% vs
36.8%; p=0.02) and diffuse pattern of infiltration (22% vs 63%; p=0.01) compared to lambda. The kappa group also had
lower MVD (9.9 vs 16.5; p=0.02) and proliferation index (4.7 vs 94; p=0.04) compared to the lambda.
Conclusion: Therefore, the type of light chain restriction is also a prognostic factor in plasma cell myeloma.
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
We use cookies and other tracking technologies to work properly, to analyze our website traffic, and to understand where our visitors are coming from. More InfoGot It!
